Replimune Group Q2 2027 Earnings Call Transcript

Replimune Group (NASDAQ:REPL) reported second-quarter financial results on Wednesday. The transcript from the company’s second-quarter earnings call has been provided below.

This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation.

View the webcast at https://edge.media-server.com/mmc/p/w84ibvfb/

Summary

Replimune Group launched its first commercial product, Tudrakev, with positive reception from the melanoma community and early adoption by major institutions.

The company has engaged over 70% of its initial target accounts, with more than 15 institutions prescribing Tudrakev within the first three weeks.

Research and development expenses decreased to $34.4 million, and the company ended the quarter with $307.8 million in cash, providing over 12 months of operational funding.

Tudrakev has been included in NCCN guidelines, with broad insurance coverage rapidly established, including Medicare.

Replimune is focused on further building its commercial team to support the Tudrakev launch, with operational workflows established in over 50 meetings with melanoma treatment centers.

Full Transcript

OPERATOR

Good day and thank you for standing by. Welcome to the Replimune Group second quarter fiscal 2027 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. To ask a question during the session, you will need to press star-1-1 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star-1-1 again.

I would now like to hand the conference over to your first speaker, Arlene Goldenberg, Head of Investor Relations. Please go ahead.

Arlene Goldenberg (Head of Investor Relations)

Thank you, Operator, and good morning everyone. Thank you for joining us for Replimune Group’s earnings call following the launch of Tudrakev. Earlier today we issued a press release reporting our financial results for the fiscal second quarter ended 9-30-20. The release accompanying today’s webcast is available in the Investors section of our website at replimune.com. With me on today’s call are Sushil Patel, our Chief Executive Officer, Michelle DiNapoli, our Chief Commercial Officer, and Emily Hill, our Chief Financial Officer.

Before we begin, I’d like to remind everyone that today’s remarks include forward-looking statements within the meaning of the federal securities laws. Items we discuss today will include forward-looking statements about topics including, but not limited to, our future financial performance, projections and assumptions about the commercial launch of Tudrakev, and management’s plans and objectives for future operations. Actual results may differ materially from those presented or implied by these forward-looking statements and are subject to risks and uncertainties that could cause actual results to differ.

We encourage you to review the risk factors in our most recent Form 10-K and Form 10-Q on file with the Securities and Exchange Commission. Any forward-looking statements that we make on this call are based on our assumptions as of today. Unless required by law, we undertake no obligation to update or revise these statements as a result of new information or future events. With that, I’ll turn the call over to Sushil.

Sushil Patel (Chief Executive Officer)

Thank you, Arlene, and thank you for joining us today. This is a defining moment for Replimune Group. Tudrakev is the first commercial product from our RPX platform. We are excited to now be delivering Tudrakev to patients, and its availability has been met with excitement from the melanoma community. We are very encouraged by the early traction, and in just the first three weeks since launch a number of leading melanoma institutions have already ordered, and many others have identified patients to treat.

The unmet need and demand are clearly there. Most of our prepared remarks on this call will focus on the commercial launch, including how we will track progress and our plans to bring Tudrakev to as many patients as possible. Michelle will provide more detail in a few moments. Importantly, the Tudrakev broad label reflects how physicians prescribe, and they’re enthusiastic that it allows them to treat a range of patients progressing on PD-1 based therapy with no requirement for prior BRAF-targeted therapy.

Since approval, we have moved with urgency and focused on the following three priorities. First and most importantly, meeting the unmet need of patients and the physicians who treat them. There are approximately 10,000 addressable patients in the U.S., and nearly 8,500 patients die of melanoma every year. Once patients fail PD-1 based therapy, treatment options are very limited, and we are seeing real urgency from healthcare providers to gain access to Tudrakev.

Next, ensuring supply is ready and getting product to patients quickly. With next-day delivery, we are ready to meet the demand with more than a year of inventory on hand produced at our in-house manufacturing facility. Finally, we are focused on attracting top talent to rebuild our commercial team. We are now almost fully staffed and right-sized to execute our launch plan. With that, I’ll turn it over to our Chief Commercial Officer, Michelle.

Michelle DiNapoli (Chief Commercial Officer)

Thank you, and good morning everyone. I am thrilled to lead the launch efforts to bring Tudrakev to patients in need. In the first few weeks of Tudrakev availability, what has struck me most is the positive reception from melanoma treaters and the sense of urgency to adopt. Both academic and community oncologists, as well as interventional radiologists, are showing real interest in using Tudrakev and are eager to include it into their practice quickly.

They value the broad label, which provides them the flexibility to treat the real-world population they see in their clinics, and appreciate the ability to bring this therapy to their patients. Tudrakev can be delivered the next day, and injections happen in the outpatient setting, so physicians can treat quickly, which matters for patients who often cannot wait. Tudrakev has been utilized by oncologists and interventional radiologists, and feedback has been positive.

We’re encouraged by the number of accounts that have identified and already started treating patients. Our top priority is setting up each account so that customers and patients have a positive first experience that supports repeat orders with optimal utilization. That is the focus of our full customer-facing team, which is in place and engaging with target customers. It includes account managers supported by our Operational Excellence Team, a cross-functional group of oncology nurses, pharmacists, and interventional radiology experts who partner with the facilities to establish Tudrakev workflows.

To date, we have held more than 50 meetings with melanoma treaters, and sites are putting treatment plans and workflows in place. We’ve been especially encouraged by the reception from interventional radiologists, and we will continue working with this group across our priority accounts to ensure image-guided injections can be done routinely. Interest is also extending beyond our initial target list of 200 accounts. We’ve received proactive outreach from community practices driven by the unmet need of their patients, and accounts with no prior Tudrakev experience have already treated patients in these first weeks. This gives us confidence that this modality can be broadly adopted. Today we aim to provide metrics to highlight the successful trajectory of our initial launch. We think about the launch as a funnel.

First, we are focused on engaging the right accounts to identify patients and drive demand for Tudrakev. Next, we secure access and establish operations to support a positive experience for both the facility and patients. Accounts then order product and patients are treated. Today, we are pleased to report our progress at each stage. First, engagement: we have had proactive engagement with more than 70% of our initial 200 target accounts, reflecting real interest in Tudrakev and our team’s ability to reach priority customers. Next, access: about 20 accounts have swiftly placed Tudrakev on formulary. And last, orders: as of Friday, over 15 institutions have written one or more Tudrakev prescriptions, a strong start in less than 20 business days. To give some additional color, some of the highest-volume melanoma institutions, including Moffitt and Memorial Sloan Kettering, have moved quickly to add Tudrakev to formulary and treat patients.

The speed of formulary action shows that access is a priority and demand is there. Additionally, other sites have told us that they are expediting, and in some cases bypassing, the usual formulary review to get Tudrakev to patients without delay. We think these examples demonstrate the unmet need and the urgency that exists to adopt Tudrakev, and momentum continues to build each week. In terms of securing coverage, Tudrakev was very rapidly listed in the NCCN guidelines as a Category 2A recommendation. To date, many commercial payers have already published policies that cover to label, which includes retreatment if clinically appropriate. We are very pleased with how rapidly these policies have been established, as they include major national and regional payers. Influencer policies that other payers commonly reference are also in place and favorable for Tudrakev coverage.

These policies already represent a majority of commercially covered lives. In addition, Medicare coverage has been established, so in totality we have rapidly secured broad coverage in line with the Tudrakev label across patients we expect to treat. We anticipate other policies to be in place in the near future. All of this progress was achieved with the miscellaneous J-code. We submitted for a permanent J-code, which we anticipate having in place by April 2027, and at that time we expect this to foster even broader adoption, including by the community.

We have also made it easier for patients to get started on Tudrakev. Replimune Group Connect Plus, our patient support program, is now live, providing a comprehensive range of support services to facilitate patient access. In summary, we are very pleased with how the first weeks of launch are going. There is clear patient demand for a well-tolerated therapy after progression on a PD-1 based regimen, and we are seeing great interest from melanoma treaters.

We are encouraged with how swiftly oncologists and interventional radiologists are adopting both superficial and image-guided injections and their ability to integrate Tudrakev into their practices. We are very excited about the early days of bringing Tudrakev to patients, and I’m confident in the team’s ability to execute. With that, I’ll turn it over to Emily.

Emily Hill (Chief Financial Officer)

Thank you, Michelle. As a reminder, Replimune Group is a March fiscal year company, so today I will provide an overview of our fiscal second quarter results. We did not record product revenue in the quarter, as first commercial shipments occurred in early October. We look forward to reporting our first product revenue in our fiscal third quarter. Research and development expenses were $34.4 million for the quarter, compared to $49.3 million in the fiscal first quarter. Selling, general, and administrative expenses were $21.9 million, compared to $19 million in the fiscal first quarter. The increase reflects the build-out of our commercial organization, including field hiring, launch readiness, and patient support programs. Net loss for the quarter was $57.1 million, compared to a net loss of $69.8 million in the fiscal first quarter.

We ended the quarter with $307.8 million in cash and cash equivalents. This includes the net proceeds of $141 million from our August offering. For reference, we held $195.3 million in cash at June 30. Based on our current operating plan, we expect our cash position will enable us to fund operations for greater than 12 months. That plan includes the commercial launch investments for Tudrakev and continued funding of Ignite3 in support of our REVEAL study in uveal melanoma.

Let me give you a few additional points to help you model the launch. The list price of Tudrakev is $450,000 per course of therapy. Before customary rebates and discounts, the actual cost per patient will vary with tumor burden and the number of cycles a patient receives, since dosing is based on the size of the lesions injected, and patients may receive eight or more cycles. Because product is shipped for each treatment visit and the course runs over several months, revenue from a patient starting therapy may be recognized over more than one quarter.

We will not be providing revenue guidance at this time. With that, operator, please open the line for questions.

OPERATOR

As a reminder, to ask a question, please press star-1-1 on your telephone and wait for your name to be announced. To withdraw your question, please press star-1-1 again. Please stand by while we compile our Q&A roster. And our first question will come from the line of Evan Segerman of BMO Capital Markets. Your line is open.

Evan Segerman (Analyst)

Hi, guys. Thank you so much for taking my question. You know, as we think about kind of the cadence of the launch and getting, you know, the large centers online, what are some of the gating factors that we should really be drilling down in our model? And as we look towards next year, appreciating that you’re not giving guidance, but any sort of metric, number of patients, or even accounts engaged that we should be thinking about as we model? Thank you so much.

Sushil Patel (Chief Executive Officer)

Thank you, Evan, for the question. Yes, in terms of some of the gating factors, I mean, so far, as we mentioned, the launch is going very, very well. We’ve really been surprised and pleased with the level of enthusiasm and the ability for customers to quickly get Tudorkev on formulary. I’m going to hand over to Michelle and then Emily to talk a little bit around some of the cadence of things that we would expect in the coming weeks and months. And then Emily will talk a little bit about the metrics, including why at this point we’re not providing patient numbers.

Michelle DiNapoli (Chief Commercial Officer)

Thank you. I think we are thinking about the launch as a funnel, as I said in my prepared remarks. We’re very excited about how we’re seeing facilities move through the process to access Tudorkev. So we think about the cadence of: are we engaging with the right melanoma treaters? Is our team able to execute and help facilities operationalize workflows? Are these accounts then ordering and identifying patients and putting plans in place to make sure it’s a seamless process?

As we’ve stated, as of this morning, we have closer to 20 accounts who have ordered and put those workflows in place and have begun treating patients, and we are continuing to see that momentum. We’re looking forward to November; several more of these facilities are coming through formulary, so we would expect them to be treating. And we think by the end of the year we could sort of double the number of accounts that we’re seeing already initiate patients.

Emily Hill (Chief Financial Officer)

Hey, Evan, I’ll just add some commentary on the metrics we’re providing now and the metrics that we think will be useful to track. We obviously thought very carefully about the metrics we could provide at this point—as we mentioned, just 20 business days into the launch—that would help you gain insight into our early success and then track our strong trajectory. As you know, Tudorkev treatment is based on a patient volume with about 1 mL per cm used for patients.

So as we see these initial robust orders come in, it is difficult for us to track the exact patient numbers. And therefore, as Michelle communicated, the most useful metrics to track at this time are those that follow the funnel: accounts on formulary and accounts that have written a first script, and we would expect to provide updates on those metrics. Once we’ve seen a cohort of patients complete their eight or more cycles, we’ll start to gain insights on the average volume used by patients in the real world, and we’ll provide further insight at a later time.

Evan Segerman (Analyst)

Great. Thank you so much.

OPERATOR

And our next question will be coming from the line of Allison Bratzel of Piper Sandler. Allison, your line is open.

Allison Bratzel (Analyst at Piper Sandler)

Hey, thanks. Good morning, and thanks for taking the questions. Just a couple for me. So I think you talked about the number of institutions that have prescribed Tudorkev. Could you talk to maybe how many have actually administered a dose and what is the typical time from prescription to first injection? And then among accounts maybe that have prescribed but not yet treated, what’s the most common holdup—access, scheduling with interventional radiology, or something else?

And then last question, just thinking about the average price per patient, I guess for patients identified and started on treatment so far, do you have a sense just on how tumor burden compares with what you saw in IGNYTE and how representative IGNYTE is of the real-world population? Thank you.

Sushil Patel (Chief Executive Officer)

Thank you, Allison. I know there’s a number of questions there, so we’ll try and break that down. Just as a reminder, though, Tudorkev is delivered the next day and can be used rapidly by accounts, and we’re definitely seeing that. I’m going to hand over to Michelle, who will cover a couple of those topics in terms of prescriptions, time to dosing, and any sort of holdups that we’ve been seeing.

Michelle DiNapoli (Chief Commercial Officer)

Yes, thank you. I think one of the features, as Sush has said, of our distribution model is that we can deliver the next day. So we have seen accounts, when they order, administering to their patients pretty quickly. We’ve seen cases where they’ve ordered on a Friday to dose a patient on Tuesday. We’ve seen instances where accounts have ordered on Monday and started the patient on Tuesday. So our distribution is working for kind of just-in-time treatment.

And I think what we’re seeing is the accounts are engaging oftentimes with us to help put their operational workflows in place with expediency because they have patients in mind, and then treat that patient pretty quickly after getting those workflows in place. In terms of the interventional radiologists in these priority accounts, we’ve seen a lot of receptivity and enthusiasm from this group as well. They’re part of that workflow process, and that’s really key. A priority for us is to ensure the oncologist and the interventional radiologist are making these plans together. We find that that is the most seamless approach. And as I said, there’s been a lot of receptivity on the part of the interventional radiologists to fit this into their approach as well.

A best practice is just being very planful—if we can schedule the patient for their eight cycles with interventional radiology when appropriate, that is working best, and we’re seeing that be syndicated in these other accounts.

Sushil Patel (Chief Executive Officer)

I think there was a question on average price and sort of volume and whether that’s going to be similar to IGNYTE. In general, Allison, I’d just say it’s a little too early to get into that. Obviously, that’s something we’re going to be monitoring as we have more data, but I’ll let Emily add any additional color to that.

Emily Hill (Chief Financial Officer)

Yeah. I think the only thing that we are watching is we do believe that IGNYTE was a representative population of the real world. What we are seeing in early days is, obviously, physicians now have experience with injecting deep visceral lesions. And as Michelle mentioned, we are seeing early adoption by interventional radiologists.

Sushil Patel (Chief Executive Officer)

Yeah, and in terms of holdups, I wouldn’t say there’s been anything that’s been a major holdup. These accounts just work at different paces, and some have been able to move very, very quickly. Others have more restricted guidance on when they have P&T, et cetera. So it’s not because the physicians within those practices are not eager to treat; it’s just sometimes they take a little longer. And we’ve got examples of accounts which said, it’s not on you guys—you provide us everything we need—it’s really on us just to go through our process, and they’re very much committed to doing that.

And in terms of your final question—well, your first question—on prescribing, all of those accounts have ordered and will be treating patients, and most of them already treated patients.

Allison Bratzel (Analyst at Piper Sandler)

Excellent. Thank you.

OPERATOR

And our next question will be coming from the line of Dana Graybosch of Leerink Partners. Your line is open.

Sushil Patel (Chief Executive Officer)

Yeah, thanks for the question. I’m going to hand that over to Michelle, who will go into some detail on that.

Michelle DiNapoli (Chief Commercial Officer)

Yes, thank you. So of the 140 accounts, I think the way that this is working is our team is engaging early on to help understand what processes they have in place. Each institution operates a little bit differently, but often the first step is getting Tudorkev on formulary so there is access within the institution. But very important—and sometimes that can be bypassed, and we’ve seen that be bypassed because patients are in need. I think overall, overarchingly, in my experience and what we’re seeing here is that when there is an unmet need, these physicians in these facilities will do what they need to to get the drug to patients.

So we’re seeing that happen here. Our team has been very successful in engaging and oftentimes being proactively asked to help partner with these facilities to put these workflows in place that include the interventional radiologist. We think that’s the best way to set these accounts up well so that they can not only have a successful first patient treatment, but also subsequent patients can go through the process and have a seamless experience. So the bottleneck isn’t really something that’s insurmountable.

It’s just working through the process, and we’re seeing every day more and more accounts come online, so to speak, so that they can successfully deliver Tudorkev. We’re also seeing accounts outside of this initial 200 that don’t have experience or haven’t had experience with Tudorkev that are figuring out the process and have successfully treated patients as well. So, as you know, we had said, that gives confidence that this can be a therapy that can be adopted quite systematically.

Sushil Patel (Chief Executive Officer)

Yeah, one thing to add maybe is we have an operational excellence team that really works cross-functionally at the site, including with pharmacy, IR, the oncologists, and really all the necessary departments and functions to make sure that we can actually address all the steps that they need to go through. And that’s been very successful so far. We’ve had more than 50 of those meetings to really make sure that all the workflows are established and things go smoothly.

So again, haven’t really seen any major holdups. As Michelle said, every account is a little different, and it just can take more time in some accounts versus others.

OPERATOR

And our next question will be coming from the line of Anupam Rama of J.P. Morgan. Your line is open.

Anupam Rama (Analyst at J.P. Morgan)

Hey, guys, thanks so much for taking the question, and congrats on some of the early progress here with the launch. I wanted to ask a quick question. In your opening comments, you talked about continuing to evolve the sales force a little bit. Can you remind us what you had in place prior to the approval regarding the sales force, where you are now, and what hires or deployment needs to happen here in the next couple weeks and months?

Michelle DiNapoli (Chief Commercial Officer)

So thank you for the question. We are very encouraged with how quickly we’ve been able to rebuild the commercial team overall. Specifically to the sales force, we have 23 account management positions that are in place and an operational excellence team that is almost fully in place. This group has been out engaging customers. As you saw, we’re having proactive engagements. We’ve penetrated over 70% of our target accounts. So we feel like we’re in a very good, copacetic state for the sales force and the customer-facing team.

And I’m sorry, now your last part of the question.

Anupam Rama (Analyst at J.P. Morgan)

Yeah. What else needs to be done in the next couple weeks and months on the sales force to get it complete?

Michelle DiNapoli (Chief Commercial Officer)

Yeah, thank you. I think we’re in good shape, and the team is just going to continue to execute in terms of driving breadth and depth in these accounts.

Sushil Patel (Chief Executive Officer)

Yeah, I think Anupam. There’s really nothing on the sales force side right now beyond just completing the training, getting out to the accounts and customers, and completing the engagement. All 200 accounts, which I think will happen quite rapidly, and then moving beyond that initial 200 to the next wave of accounts. But really on the sales force and Michelle’s team, there really isn’t much. There’s a couple of internal positions we’re trying to hire which should be filled very quickly.

OPERATOR

And our next question will come from the line of Roger Song of Jefferies. Roger, your line is open.

Roger Song (Analyst at Jefferies)

Great. Thanks for taking the question. A couple quick ones. One is, do you have some visibility regarding the patients being treated and intended to be treated? Are they superficial-only patients or lesion patients, or a visceral mix? And then also in terms of formulary, when a drug is put on the formulary, do they have some limitation on how much the volume could be reimbursed? Is that up to 80 milliliters, or that’s based on the tumor volume? And just lastly, when you launch, get approval, you have some rough timeline on the focus: six months for the early adopter and the next nine to 12 months for the next wave, 450 accounts.

Just curious, now you’re thinking, based on the experience you have, if this timeline can be accelerated, and then how should we think about the site engagement versus the first order from those two waves, 200 accounts and then 450 accounts? Thank you.

Sushil Patel (Chief Executive Officer)

Just to take your first question, no, we’re definitely seeing adoption of both superficial as well as image-guided injections. And as you know, Roger, this has been a big focus of ours. We really believe to sort of maximize the opportunity and benefit for patients that we need to do those image-guided injections. And in these early few weeks, we’re definitely seeing those image-guided injections already happening, which is, I think, encouraging. It’s something that we’ll continue to focus on.

I’ll let Michelle talk about formulary. My only comment on formulary is a lot of it is actually dependent on the payer policies, and they haven’t restricted us in any way in terms of retreatment. So I wouldn’t expect the institutional formularies to be more restrictive than the payer formularies. But Michelle, you can comment on that.

Michelle DiNapoli (Chief Commercial Officer)

Yes, I think that’s exactly right. So the short answer is no, we’re not seeing any restrictions on formulary in terms of usage. All have been supportive of the label. I think importantly, as Sushil had said, we are very encouraged with how quickly published policies have been put in place, and these are really exactly to the TudorKev label, supporting not only the 8 cycles, but retreatment as necessary. There are no volume restrictions in any of these published policies.

In fact, some of the policies allow for doses up to 24. So if the label is 8 and then retreatment, but nothing on volume, which is obviously very encouraging. Then your next question was around launch success. And yes, our priority in the first six months we’ve said is in these top 200 accounts. That is because they cover a high concentration of melanoma patients, about 30% that are treated nationally each year within the U.S. We plan to think about accelerating the next wave of 250 accounts. That would represent another 20% of the melanoma population. Some of these places have already proactively engaged with us.

Some have already begun treating patients on their own, which just, I think, reflects the demand that’s out there and the unmet need that is out there. So we will continue to assess accelerating, moving into these sort of regional centers and then into the community as swiftly as possible.

Sushil Patel (Chief Executive Officer)

But I think, Roger, as Michelle said, what’s important for us is we do this right. And I think if we’re going to optimize treatment and get repeat treatments and have a really good patient and physician experience, we want to make sure we do it right. So certainly, if we’re ready to accelerate into that next wave, given how good the early traction has been, we’ll certainly be able and ready to do that. But we’ll do it at the right time when we feel it’s ready and that we’ve fully penetrated those 200 accounts.

Roger Song (Analyst at Jefferies)

Excellent. Thank you.

OPERATOR

And our next question will be coming from Mubin Mosheheb of Cantor. Your line is open.

Mubin Mosheheb (Analyst at Cantor)

Hey, good morning. This is Mubin. Congrats on all the progress and on the first treatment. I have one particular question on the superficial versus the deep injections. Can you talk about the proportion of patients getting a superficial injection versus a deep injection, and how does that affect the volume of treatment? Thank you.

Sushil Patel (Chief Executive Officer)

I’m sorry, could you repeat the question on the— I think I got the volume. Was it the volume used for superficial versus deep?

Mubin Mosheheb (Analyst at Cantor)

Yeah, exactly. Yeah.

Sushil Patel (Chief Executive Officer)

Again, it’s too early to comment on volume differences by lesion type and lesion location. In the past, when we’ve looked at this on IGNYTE, we have seen that when you do deep injections such as lung and liver, they tend to have a higher volume. But again, even the superficial will depend on how many superficial lesions the patient has. Every patient’s a little different, so it’s really hard to sort of generalize that volume will be different for superficial versus deep, particularly at this point in the launch.

Mubin Mosheheb (Analyst at Cantor)

Okay, thank you.

OPERATOR

And our next question will be coming from the line of Rami O’Connor of Kempen. Your line is open. Rami.

Rami O’Connor (Analyst at Kempen)

Hi team. Thank you so much for the presentation today and for my questions. I have two. So the first of the 15-plus institutions that have prescribed TudorKev, can you provide some color on what centers these actually represent? So are they predominantly the larger academic centers? Are you also seeing the adoption across more regional community centers? And how does that mix compare with your initial expectations? And then a second, maybe more broader question would be with the evolving treatment landscape in PD-1 refractory melanoma. I’m just curious to hear your view on how you think physicians are positioning TudorKev in clinical practice. It might be too early to say, but are you seeing preference for immediate use or still post-checkpoints? Thank you.

Michelle DiNapoli (Chief Commercial Officer)

So to your question around characterization of our top initial treaters in the 15 accounts, these are mostly within our expectations. These are purposefully academic and hospital-based centers. We expected these to be the first adopters because these are institutions that have intratumoral experience, they may have been involved in our clinical trials, they have IR on board, they’re confident with the miscellaneous J code. So, as expected, the majority of these accounts are those, and they tend to be sort of the higher-volume melanoma centers in the country.

So as expected, a lot of these accounts are from that group. But what has been surprising is there are a few that are from the more regional centers that have adopted very, very quickly and very successfully to use TudorKev in both superficial and deep injections. So we’re excited about that progress, and we’re continuing to see beyond the 15. We’re continuing to see the early adopter accounts, or the priority one accounts, continue to accelerate and momentum build in terms of them working through their processes, identifying patients, and we expect to see even more continue to come on board in the next weeks and months.

Sushil Patel (Chief Executive Officer)

In terms of your question on the treatment landscape and how we are seeing sort of TudorKev already being positioned, you are right, it’s a little too early. But as a reminder, we have a really broad label that allows patients to be treated on progression of whatever PD-1–based treatment they were on before. That includes patients from the adjuvant setting, front line, second line, et cetera. So we would very much expect physicians, and what we’re hearing is, they’re willing to use it early as well as in some cases later-line patients, depending on what the need is at the time.

Rami O’Connor (Analyst at Kempen)

Super clear. Thank you.

OPERATOR

And I would now like to hand the conference back to Sasho for closing remarks.

Sushil Patel (Chief Executive Officer)

Thank you, operator, and thank you all for your questions, for joining us today. Before we close, I just wanted to share a few final thoughts. We’re very proud of what this team has accomplished, and we’re excited about what is ahead. TudorKev is approved with a broad, practical label, and physician enthusiasm is evident. Early adoption has been very encouraging. The commercial launch of TudorKev is our number one priority, and we are focused on bringing TudorKev to a broad range of patients in need.

Our REVEAL study of RP2 in uveal melanoma, as well as our confirmatory melanoma study I3, which is now open to additional sites in Europe, are both enrolling very well. We look forward to sharing updates on these studies and our pipeline at upcoming investor conferences. Thank you for your time.

OPERATOR

And this concludes today’s program. Thank you for participating. You may now disconnect.

Disclaimer: This transcript is provided for informational purposes only. While we strive for accuracy, there may be errors or omissions in this automated transcription. For official company statements and financial information, please refer to the company’s SEC filings and official press releases. Corporate participants’ and analysts’ statements reflect their views as of the date of this call and are subject to change without notice.